<?xml version="1.0"?>
<?xml-stylesheet type="text/xsl" href="billres.xsl"?>
<!DOCTYPE bill PUBLIC "-//US Congress//DTDs/bill.dtd//EN" "bill.dtd">
<bill bill-stage="Introduced-in-House" dms-id="H485B5AD8F91743D7BC3E72F95D6A5FAF" public-private="public" key="H" bill-type="olc"><metadata xmlns:dc="http://purl.org/dc/elements/1.1/">
<dublinCore>
<dc:title>118 HR 5074 IH: Kidney Patient Access to Technologically Innovative and Essential Nephrology Treatments Act of 2023</dc:title>
<dc:publisher>U.S. House of Representatives</dc:publisher>
<dc:date>2023-07-28</dc:date>
<dc:format>text/xml</dc:format>
<dc:language>EN</dc:language>
<dc:rights>Pursuant to Title 17 Section 105 of the United States Code, this file is not subject to copyright protection and is in the public domain.</dc:rights>
</dublinCore>
</metadata>
<form>
<distribution-code display="yes">I</distribution-code><congress display="yes">118th CONGRESS</congress><session display="yes">1st Session</session><legis-num display="yes">H. R. 5074</legis-num><current-chamber>IN THE HOUSE OF REPRESENTATIVES</current-chamber><action display="yes"><action-date date="20230728">July 28, 2023</action-date><action-desc><sponsor name-id="C001103">Mr. Carter of Georgia</sponsor> (for himself, <cosponsor name-id="K000382">Ms. Kuster</cosponsor>, <cosponsor name-id="M001205">Mrs. Miller of West Virginia</cosponsor>, and <cosponsor name-id="S001185">Ms. Sewell</cosponsor>) introduced the following bill; which was referred to the <committee-name committee-id="HIF00">Committee on Energy and Commerce</committee-name>, and in addition to the Committee on <committee-name committee-id="HWM00">Ways and Means</committee-name>, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned</action-desc></action><legis-type>A BILL</legis-type><official-title display="yes">To amend the American Taxpayer Relief Act of 2012 to delay implementation of the inclusion of oral-only ESRD-related drugs in the Medicare ESRD prospective payment system.</official-title></form><legis-body id="H815C61F52C8040DC9FFC1A4C58085806" style="OLC"><section id="HE05BD984C47E4440840BCB1095D3A38A" section-type="section-one"><enum>1.</enum><header>Short title</header><text display-inline="no-display-inline">This Act may be cited as the <quote><short-title>Kidney Patient Access to Technologically Innovative and Essential Nephrology Treatments Act of 2023</short-title></quote> or the <quote><short-title>Kidney PATIENT Act of 2023</short-title></quote>.</text></section><section id="H526FF6A852424A178CB36CE51EE6029D" section-type="subsequent-section"><enum>2.</enum><header>Delay of implementation of oral-only policy under Medicare ESRD prospective payment system</header><text display-inline="no-display-inline">Section 632(b) of the American Taxpayer Relief Act of 2012 (<external-xref legal-doc="usc" parsable-cite="usc/42/1395rr">42 U.S.C. 1395rr</external-xref> note) is amendedâ€”</text><paragraph id="H5EE006BCF437483D9AC25950AC0F9E8E"><enum>(1)</enum><text display-inline="yes-display-inline">in the heading, by striking <quote><header-in-text level="subparagraph" style="OLC">Two-year</header-in-text></quote>; and</text></paragraph><paragraph id="HD335E0EAB73A48C4A08A51C420BB9E28"><enum>(2)</enum><text display-inline="yes-display-inline">in the first sentence of paragraph (1), by striking <quote>may not implement</quote> and all that follows through <quote>January 1, 2025.</quote> and inserting <quote>shall not implement the policy under section 413.174(f)(6) of title 42, Code of Federal Regulations (relating to oral-only ESRD-related drugs in the ESRD prospective payment system) to incorporate the payment for oral drugs indicated for the reduction, management, or control of the serum phosphate of an individual, until the earlier of January 1, 2033, or such time as an intravenous drug indicated for the reduction, management, or control of the serum phosphate of an individual has been approved by the Food and Drug Administration.</quote>.</text></paragraph></section></legis-body></bill> 

